Improving RNA replication for vaccines and therapies
Official title: Make an OFERR: Optimization for Enhanced RNA Replication
Funded at Lynntech, INC. · NIH-10921608 · Data updated 2026-11-12
This study is exploring a new way to use special RNA molecules to help make better vaccines and treatments by improving how they work in our bodies, and it's designed for anyone interested in advancements in medical therapies.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lynntech, INC. NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project start | September 19, 2024 |
| Project end | September 18, 2025 |
| Funding year | 2024 |
| Award (this year) | $283,304 |
| NIH project number | 1R43GM150366-01A1 |
| Project ID | NIH-10921608 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals who may benefit from RNA-based vaccines or therapies, particularly those with infectious diseases or cancers.
✕Less likely to help
Patients who do not have conditions that could be treated with RNA-based therapies may not receive any benefit from this research.
What this research studies
This research focuses on self-amplifying RNAs (saRNAs), which are engineered from RNA viruses to enhance the production of therapeutic proteins. By replacing viral structural genes with genes of interest, the saRNAs can replicate within host cells, leading to prolonged expression of the desired proteins. The project aims to develop software using machine learning to optimize the replication process of these saRNAs, potentially improving their effectiveness as vaccines and treatments. This innovative approach could reduce the amount of RNA needed while maintaining strong immune responses.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and therapies with longer-lasting effects and reduced dosage requirements.
How similar studies have gone: There have been successful clinical trials involving self-amplifying RNAs by major pharmaceutical companies, indicating the potential of this approach.
Where this research is happening
-
Lynntech, INC.
College Station, United States Active
Researchers
- Principal investigator: Gorzelnik, Karl — Lynntech, INC.
- Study coordinator: Gorzelnik, Karl
Related research
Other NIH-funded projects on the same topics.
-
BREATHWISE: an AI-based early warning for COPD flare-ups
A personalized AI-powered system using wearables and phones to spot signals that a COPD flare-up may be coming so patients and clinicians can intervene earlier.
-
Rapid, on-site test for Shiga toxin–producing E. coli in irrigation water
A new on-site device will quickly identify harmful STEC bacteria in irrigation water to help keep fresh produce safe.
-
A method to deliver multiple antibodies for HIV-1 treatment
This study is exploring a new way to deliver a combination of powerful antibodies in one shot to help improve treatment for people living with HIV-1, making it easier and more effective to fight the virus.
-
A gel that delivers a new treatment for diabetic foot ulcers
This study is testing a special gel that helps deliver a medicine to speed up the healing of diabetic foot ulcers, which are painful sores that can happen to people with diabetes.
-
A new method to detect RNA from bloodborne viruses like HIV and hepatitis C
This study is working on a new test that makes it easier to find HIV and hepatitis C in blood samples, which could help people get more accurate results, especially in places where resources are limited.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.